How to manage essential thrombocythemia (Q37952488)

25 August 2017

How to manage essential thrombocythemia (English)

1 reference

25 August 2017

G Finazzi

1

1 reference

25 August 2017

4 November 2011

1 reference

25 August 2017

1 reference

25 August 2017

26

1 reference

25 August 2017

5

1 reference

25 August 2017

875-882

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2011.306

25 August 2017

0 references

cites work

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Bone marrow histopathology in myeloproliferative disorders--current diagnostic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Hemostatic complications in young patients with essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

No treatment for low-risk thrombocythaemia: results from a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

A long-term retrospective study of young women with essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Efficacy and safety of low-dose aspirin in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Pregnancy and its management in the Philadelphia negative myeloproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

Interferon-alpha in the treatment of essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

Clinical course of essential thrombocythemia in 147 cases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.306

7 January 2021

Identifiers

DOI

10.1038/LEU.2011.306

1 reference

25 August 2017

1 reference

PubMed ID

22051530